Alzheimer's break­through? Not so fast — ex­perts poke holes in da­ta un­der­ly­ing Chi­na's sur­prise ap­proval

No new drug has been ap­proved for Alzheimer’s since 2003, and re­searchers en­deav­or­ing to change that have been greet­ed with a grave­yard of failed ther­a­pies. So when Chi­nese reg­u­la­tors waved a treat­ment de­vel­oped by an ob­scure biotech through to the mar­ket — al­beit a con­di­tion­al ap­proval con­tin­gent up­on con­fir­ma­to­ry da­ta — it makes sense that sci­en­tists who woke up to the news were more in doubt than in awe.

While sev­er­al promi­nent Alzheimer’s ex­perts threw their weight be­hind the sea­weed-de­rived ther­a­py, oligo­man­nate (GV-971), oth­ers con­tact­ed by End­points News were much more skep­ti­cal. As Green Val­ley Phar­ma has yet to re­lease full da­ta of the sin­gle Phase III tri­al on which the de­ci­sion was based, most are tak­ing a wait-and-see stance while the com­pa­ny pre­pares to launch a sec­ond, glob­al tri­al in ear­ly 2020.

Among the del­uge of ques­tions sur­round­ing the sur­prise ap­proval, two seem par­tic­u­lar­ly cru­cial: Did Green Val­ley of­fer enough cred­i­ble ev­i­dence to war­rant an OK? And did the drug re­al­ly work as the biotech claimed?

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER